Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients

Table 2

Multivariate Cox regressions analysis of predictors of development of advanced liver fibrosis (FIB-4 > 3.25).

	Unadjusted HR (95% CI)		Adjusted HR (95% CI)
Time-independent baseline covariates
Hyponatremia at transplant	1.49 (1.1–2.02)	0.01	1.48 (1.09–2.01)	0.01
MELD	1 (0.98–1.02)	0.9	1 (0.99–1.02)	0.63
Time updated covariates
Diabetes	1.37 (1.01–1.86)	0.04	1.34 (0.98–1.83)	0.06
Hypoalbuminemia	2.55 (1.91–3.4)	<0.001	2.31 (1.72–3.09)	<0.001
CMV pos recipient	1.43 (1.02-2)	0.04	1.36 (0.97–1.892)	0.08
Cyclosporine	0.99 (0.73–1.35)	0.9	1.04 (0.77–1.42)	0.27
Chronic HCV	4.35 (3.22–5.88)	<0.001	3.96 (2.92–5.36)	<0.001

HR, hazard ratio; CI, confidence interval; MELD, model for end-stage liver disease; CMV, cytomegalovirus; HCV, hepatitis C virus.